Yamanouchi Vaprisol review
Executive Summary
FDA's Endocrinologic & Metabolic Drugs Advisory Committee will review Yamanouchi's Vaprisol (conivaptan) for treatment of nonhypovalemic hyponatremia (water poisoning) in hospitalized patients on Sept. 9. The meeting will be held at the CDER advisory committee conference room in Rockville, Md...